Teva (TEVA) calls active after patent board says certain claims of Copaxone patent invalid

August 24, 2016 3:42 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Teva Pharma (NYSE: TEVA) August 55 and 57.50 calls are active on total call volume of 25K contracts (15K puts) after the U.S. Patent and Trademark Office's Patent Trial and Appeal Board, or PTAB, determined that Mylan Pharmaceuticals (MYL) and Amneal Pharmaceuticals, as co-petitioners, met their "burden of proving the unpatentability of claims 1-20 of '250 patent by a preponderance of the evidence." August call option implied volatility is at 47, September is at 38; compared to its 52-week range of 16 to 49.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Options, Trader Talk

Related Entities

Options, myl

Add Your Comment